中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

402 records (took 0.018 seconds)

    ANDROGEN-MEDIATED NEUROPROTECTION AND USES THEREOF
    43.
    发明申请
    ANDROGEN-MEDIATED NEUROPROTECTION AND USES THEREOF 审中-公开
    雄激素介导的神经保护及其用途

    公开(公告)号：WO02087552A3

    公开(公告)日：2003-10-02

    申请号：PCT/CA0200668

    申请日：2002-04-30

    Applicant: UNIV MCGILL ,  LEBLANC ANDREA ,  GELFAND MORRIE ,  TRIFIRO MARK

    Inventor： LEBLANC ANDREA ,  GELFAND MORRIE ,  TRIFIRO MARK

    IPC: A61K31/00 ,  A61K31/565 ,  A61K31/568 ,  A61K31/569 ,  A61P25/00

    CPC classification number: A61K31/568 ,  A61K31/569

    Abstract: Androgens, such as testosterone, methyltestosterone, and epitestosterone, are disclosed herein as being neuroprotective, in that they inhibit or prevent cell death or apoptosis of neural cells. A neuroprotective effect of androgens on primary cultures of human neurons with respect to serum deprivation-mediated apoptosis and amyloid beta peptide mediated neurotoxicity is described. The invention thus provides methods and uses of androgens as well as compositions and commercial packages comprising androgens for the prevention and/or treatment of neural or neurodegenerative disease and for the prevention and/or inhibition of cell death. The invention further provides methods of identifying and screening compounds for the prevention and/or treatment of neural or neurodegenerative disease.

    Abstract translation: 雄激素如睾酮，甲睾酮和表睾酮在本文中被公开为神经保护，因为它们抑制或预防神经细胞的细胞死亡或细胞凋亡。 描述了雄激素对人神经元原代培养物相对于血清剥夺介导的细胞凋亡和淀粉样蛋白β介导的神经毒性的神经保护作用。 因此，本发明提供了雄激素以及包含雄激素用于预防和/或治疗神经或神经变性疾病以及预防和/或抑制细胞死亡的组合物和商业包装的方法和用途。 本发明还提供鉴定和筛选用于预防和/或治疗神经或神经变性疾病的化合物的方法。

    TRANSDERMAL THERAPEUTIC SYSTEM CONTAINING TESTOSTERONE AND METHOD FOR THE PRODUCTION THEREOF
    46.
    发明申请
    TRANSDERMAL THERAPEUTIC SYSTEM CONTAINING TESTOSTERONE AND METHOD FOR THE PRODUCTION THEREOF 审中-公开
    含睾酮透皮治疗系统及其制造方法

    公开(公告)号：WO02066018A3

    公开(公告)日：2003-04-24

    申请号：PCT/EP0201258

    申请日：2002-02-07

    Applicant: LOHMANN THERAPIE SYST LTS ,  THEOBALD FRANK

    Inventor： THEOBALD FRANK

    IPC: A61K9/70 ,  A61K31/568 ,  A61K47/08 ,  A61K47/10 ,  A61K47/14 ,  A61K47/18 ,  A61K47/22 ,  A61K47/32 ,  A61K47/34 ,  A61K47/38 ,  A61P5/26 ,  A61P15/08 ,  A61P31/18 ,  A61P35/00

    CPC classification number: A61K9/7061 ,  A61K31/568

    Abstract: The invention relates to a transdermal therapeutic system for providing sexual hormones, containing a rear coating which is impermeable for active ingredients, an adhesive polymer matrix joined thereto containing a sexual hormone and substances promoting skin penetration, in addition to a protective layer which can be removed before application. The invention is characterised in that the polymer matrix contains the sexual hormone testosterone and a mixture containing at least one substance from the group comprising fatty alcohol esters and fatty acid esters, which promote penetration, and at least one penetration-promoting substance which is easily volatile.

    Abstract translation: 对于性激素的给药的透皮治疗系统，其包括一个活性物质不可渗透的背查看包含性激素相关联的压敏粘合剂的聚合物基质，和皮肤渗透增强剂，和可拆卸的应用之前保护层，其特征在于，所述聚合物基质中的性激素睾酮，以及 从脂肪醇酯和脂肪酸酯的至少一种渗透促进物质和至少一种基团的包含挥发性渗透促进物质的混合物含有。

    DRYING METHOD FOR SELECTIVELY REMOVING VOLATILE COMPONENTS FROM WET COATINGS
    49.
    发明申请
    DRYING METHOD FOR SELECTIVELY REMOVING VOLATILE COMPONENTS FROM WET COATINGS 审中-公开
    干燥方法可选择从湿涂层中去除挥发性成分

    公开(公告)号：WO02025194A1

    公开(公告)日：2002-03-28

    申请号：PCT/US2001/042248

    申请日：2001-09-21

    IPC: A61J3/00 ,  A61K9/70 ,  A61K31/21 ,  A61K31/439 ,  A61K31/465 ,  A61K31/568 ,  A61K47/10 ,  A61K47/12 ,  A61K47/14 ,  A61K47/34 ,  A61P1/08 ,  A61P5/24 ,  A61P9/10 ,  A61P25/34 ,  B01D5/00 ,  F26B3/20 ,  F26B13/10 ,  F26B25/00

    CPC classification number: A61K9/7061 ,  B01D5/0066 ,  F26B3/20 ,  F26B13/105 ,  F26B25/006

    Abstract: Method of selectively removing volatile components from a composition, comprising coating the composition onto a first substrate surface of a substrate (38), wherein the composition comprises a nonresident volatile component and a resident volatile component. The method further includes positioning at least a portion of the coated substrate (36) between a condensing surface (32) having a condensing surface temperature (Tc) and a heating surface (34) having a heating surface temperature (TH) that is greater than the condensing surface temperature, wherein the condensing surface (32) is in a spaced apart, confronting relationship to the coated surface (44) of the substrate (38) and wherein the heated surface (34) is in thermal contact with a second substrate surface (42) opposite the first substrate surface. In the method, the heated surface temperature (TH) and the condensing surface temperature (Tc) are such that the positioning step causes the nonresident volatile component to be selectively removed from the portion of the coated substrate. The method is suitable for forming transdermal drug delivery compositions (36).

    Abstract translation: 从组合物中选择性除去挥发性组分的方法，包括将组合物涂覆在基材（38）的第一基材表面上，其中所述组合物包含非驻留挥发性组分和驻留挥发性组分。 该方法还包括将涂覆的基底（36）的至少一部分定位在具有冷凝表面温度（Tc）的冷凝表面（32）和加热表面温度（TH）之间的加热表面温度（TH）大于 冷凝表面温度，其中冷凝表面（32）与衬底（38）的涂覆表面（44）处于间隔开的面对关系，并且其中加热表面（34）与第二衬底表面 （42）与第一基板表面相对。 在该方法中，加热的表面温度（TH）和冷凝表面温度（Tc）使得定位步骤使得非常规挥发性组分从涂覆的基底的部分选择性地去除。 该方法适用于形成透皮药物递送组合物（36）。

    METHOD OF INCREASING TESTOSTERONE AND RELATED STEROID CONCENTRATIONS IN WOMEN
    50.
    发明申请
    METHOD OF INCREASING TESTOSTERONE AND RELATED STEROID CONCENTRATIONS IN WOMEN 审中-公开
    增加孕激素和相关的甾体浓度在妇女中的方法

    公开(公告)号：WO02017967A1

    公开(公告)日：2002-03-07

    申请号：PCT/US2001/027199

    申请日：2001-08-29

    IPC: A61K9/06 ,  A61K9/00 ,  A61K31/565 ,  A61K31/568 ,  A61K47/10 ,  A61K47/12 ,  A61K47/14 ,  A61K47/32 ,  A61P3/04 ,  A61P3/06 ,  A61P3/10 ,  A61P3/14 ,  A61P5/24 ,  A61P5/48 ,  A61P9/00 ,  A61P9/10 ,  A61P9/12 ,  A61P15/02 ,  A61P15/08 ,  A61P15/10 ,  A61P15/12 ,  A61P19/10 ,  A61P21/06 ,  A61P25/18 ,  A61P25/24 ,  A61P25/28 ,  A61P27/12 ,  A61P31/18 ,  A61P35/00 ,  C07J1/00

    CPC classification number: A61K31/568 ,  A61K9/0014 ,  A61K31/565 ,  A61K31/5685 ,  A61K45/06 ,  A61K47/10 ,  A61K47/12 ,  A61K47/14 ,  A61K47/32 ,  A61K2300/00

    Abstract: The present invention relates to methods, kits, combinations, and compositions for treating, preventing or reducing the risk of developing a testosterone deficient disorder, or the symptoms associated with, or related to a testosterone deficient disorder in a female mammal in need thereof. The present invention also relates to a method of administering a steroid in the testosterone synthetic pathway, for example testosterone, to a mammal in need thereof. In addition, the methods, kits, combinations and compositions may be used in conjunction with other pharmaceutical agents effective at treating, preventing, or reducing the risk of developing a testosterone deficient disorder. The methods, kits, combinations and compositions can also be used in conjunction with a pharmacologically effective amount of an estrogenic hormone, for example, estradiol. Furthermore, the methods, kits, combinations and compositions can be used in conjunction with a pharmacologically effective amount of another steroid or pharmaceutical agent that increases serum testosterone levels in a mammal, for example, methyltestosterone.

    Abstract translation: 本发明涉及用于治疗，预防或降低发生睾酮缺乏症的风险的方法，试剂盒，组合和组合物，或与有需要的雌性哺乳动物相关或与睾丸激素缺乏症有关的症状。 本发明还涉及向有需要的哺乳动物施用类固醇在睾酮合成途径例如睾酮中的方法。 此外，方法，试剂盒，组合和组合物可以与有效治疗，预防或降低发展睾酮缺乏症的风险的其它药剂结合使用。 方法，试剂盒，组合和组合物也可以与药理学有效量的雌激素，例如雌二醇联合使用。 此外，方法，试剂盒，组合和组合物可以与药理学有效量的另一种类固醇或药剂联合使用，其可增加哺乳动物例如甲基睾酮中的血清睾酮水平。

Patent Agency Ranking